J. Powderly

发表

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

H. Kohrt, P. Hegde, R. Herbst, 2014, Nature.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

David C. Smith, J. Taube, M. Atkins, 2012, The New England journal of medicine.

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

David C. Smith, A. Drilon, J. Wolchok, 2019, JAMA oncology.

Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers.

A. Hotson, E. Piccione, Richard A. Miller, 2019, Journal of Clinical Oncology.

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Israel Lowy, Mark Selby, Drew M Pardoll, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.

Manish R. Patel, J. Nemunaitis, A. Heydebreck, 2016 .

Microtube device for selectin-mediated capture of viable circulating tumor cells from blood.

B. Greene, M. King, J. Powderly, 2012, Clinical chemistry.

Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.

J. Taube, C. Horak, M. Atkins, 2014 .

Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor.

S. Pillemer, P. LoRusso, Lieping Chen, 2013 .

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.

David C. Smith, L. Sequist, F. Hodi, 2014 .

Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients

K. Blackwell, H. Lyerly, M. Morse, 2011, Clinical Cancer Research.

Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.

G. Giaccone, F. Hodi, S. Gettinger, 2017 .

Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors

S. Loi, M. Hellmann, L. Emens, 2017 .

Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study

F. Hodi, L. Molinero, J. Bendell, 2020, Clinical Cancer Research.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Keunchil Park, N. Rizvi, J. Mazières, 2018, The Lancet. Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

David C. Smith, J. Wolchok, C. Drake, 2010 .

A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies.

J. Sosman, C. Drake, D. Smith, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors

David C. Smith, L. Sequist, S. Gettinger, 2017 .

Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.

J. Sosman, F. Hodi, S. Gettinger, 2013 .

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

David C. Smith, L. Sequist, F. Hodi, 2014 .

Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients.

A. Wozniak, E. Felip, J. Chaft, 2018 .

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors.

H. Kohrt, J. Tabernero, Daniel S Chen, 2013 .

Immunotherapy earns its spot in the ranks of cancer therapy

M. Sznol, J. Sosman, J. Powderly, 2012 .

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.

Keunchil Park, N. Rizvi, J. Mazières, 2020, Lung cancer.

Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

P. Hegde, J. Sosman, F. Hodi, 2019, Clinical Cancer Research.

The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma

S. O’Day, E. Hersh, W. Urba, 2007 .

Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine

A. Pavlick, S. O’Day, E. Hersh, 2008 .

7003 ORAL Ipilimumab (MDX-010) in patients with unresectable stage III or IV malignant melanoma: efficacy and safety data from a phase I trial

S. O’Day, E. Hersh, W. Urba, 2007 .

DURABLE RESPONSES AND LONG-TERM PROGRESSION- FREE SURVIVAL OBSERVED IN A PHASE II STUDY OF MDX- 010 ALONE OR IN COMBINATION WITH DACARBAZINE (DTIC) IN METASTATIC MELANOMA.

A. Pavlick, S. O’Day, E. Hersh, 2005 .

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

K. Flaherty, A. Ribas, P. Moore, 2015, Journal of Immunotherapy for Cancer.

Abstract 2651: Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma

P. Hegde, H. Hurwitz, J. Bendell, 2016 .

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.

J. Nemunaitis, R. Doebele, M. Hellmann, 2017 .

Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial

J. Taube, C. Horak, M. Atkins, 2016 .

Abstract CT177: Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study

J. Nemunaitis, Gongfu Zhou, A. Naing, 2018, Clinical Trials.

Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors

David C. Smith, R. Kurek, P. LoRusso, 2016, Cancer Chemotherapy and Pharmacology.

757 A phase 1/1b dose escalation and cohort expansion study of MGC018 in combination with lorigerlimab in patients with advanced solid tumors (AST)

J. Powderly, E. Shenderov, P. Kaminker, 2022, Regular and Young Investigator Award Abstracts.

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

R. Ferris, N. Rizvi, B. Keam, 2020, Clinical Cancer Research.

Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.

David C. Smith, T. Choueiri, M. Atkins, 2013 .

Host Absence of CCR5 Potentiates Dendritic Cell Vaccination1

J. Serody, Robin R. Craven, S. Kirby, 2003, The Journal of Immunology.

Phase I/II study of ipilimumab for patients with metastatic melanoma.

S. O’Day, E. Hersh, W. Urba, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

M. Dhodapkar, M. Sznol, H. Kluger, 2014, Science Translational Medicine.

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

David C. Smith, T. Choueiri, M. Atkins, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

David C. Smith, J. Taube, M. Atkins, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

A. Pavlick, S. O’Day, E. Hersh, 2011, Investigational New Drugs.

Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

T. Powles, D. Shaffer, D. Petrylak, 2021, Clinical Cancer Research.

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial

S. Adams, L. Molinero, J. Diamond, 2019, JAMA oncology.

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

P. Hegde, T. Powles, J. Sosman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

David C. Smith, L. Sequist, S. Gettinger, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study

N. Rizvi, J. Mazières, J. Vansteenkiste, 2017 .

Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).

David C. Smith, M. Atkins, J. Sosman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

David C. Smith, J. Sosman, L. Sequist, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

J. Sosman, R. Herbst, F. Hodi, 2013 .

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial

J. Nemunaitis, C. Verschraegen, A. von Heydebreck, 2019, JAMA oncology.

Differential drug responses of circulating tumor cells within patient blood.

B. Greene, M. King, J. Powderly, 2014, Cancer letters.

Phase II Study Evaluating the Effect of Concomitant Ramucirumab on the Pharmacokinetics of Docetaxel in Patients with Advanced Solid Tumors

David C. Smith, D. Shepard, Ling Gao, 2016 .

First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

G. Demetri, P. Sharma, A. Tolcher, 2021, Clinical Cancer Research.

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

A. Tolcher, A. Italiano, M. Tanner, 2020, Clinical and translational science.

Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial

L. Molinero, F. Kabbinavar, I. Braña, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

T. Choueiri, R. Heist, M. Sznol, 2019, Cancer discovery.

Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).

David C. Smith, T. Choueiri, M. Atkins, 2012 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).

S. Adams, L. Molinero, J. Diamond, 2016 .

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non – Small-Cell Lung Cancer : Results From the CA 209-003 Study

David C. Smith, Julie, L. Sequist, 2018 .

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

G. Giaccone, F. Hodi, S. Gettinger, 2018, European journal of cancer.

Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors.

David C. Smith, L. Chow, D. Shepard, 2014 .

Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.

David C. Smith, J. Taube, M. Atkins, 2013 .

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

T. Choueiri, R. Heist, M. Sznol, 2019 .

Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies

C. Drake, I. Lowy, A. Korman, 2008 .

Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.

David C. Smith, R. Motzer, T. Choueiri, 2016 .

Prolonged survival in objective responders to ipilimumab therapy

F. Hodi, S. O’Day, E. Hersh, 2008 .

Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every 3 weeks for 4 doses (induction dosing)

S. O’Day, E. Hersh, W. Urba, 2008 .

A phase 1b/2, open-label study to evaluate the safety and tolerability of MEDI6469 in combination with immune therapeutic agents or therapeutic mAbs in patients with selected advanced solid tumors or aggressive B-cell lymphomas.

D. Mahadevan, F. Braiteh, Y. Chae, 2015 .

Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine.

S. O’Day, E. Hersh, W. Urba, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.

P. LoRusso, S. Piha-Paul, Christina Wu, 2019 .

1141PDCA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study

J. Lee, M. Ahn, Y. Bang, 2017 .

Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas.

J. Infante, A. Daud, Hongwei Wang, 2017 .

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study

J. Berlin, A. Mansfield, J. Nemunaitis, 2022, Journal for ImmunoTherapy of Cancer.

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).

H. Hurwitz, J. Bendell, M. Pishvaian, 2015 .

Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors.

R. Ferris, N. Rizvi, V. Chiou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples

B. Greene, M. King, J. Powderly, 2012, Journal of visualized experiments : JoVE.

Dhodapkar NY-ESO-1 to the Dendritic Cell Receptor DEC-205 Induction of Antigen-Specific Immunity with a Vaccine Targeting

M. Dhodapkar, M. Sznol, H. Kluger, 2014 .

The application of autologous cancer immunotherapies in the age of memory-NK cells

M. Torres-Lugo, J. Powderly, Renaud F. Warin, 2023, Frontiers in Immunology.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

J. Taube, C. Drake, Lieping Chen, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.

J. Nemunaitis, C. Verschraegen, A. Dowlati, 2018 .

Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis.

David C. Smith, T. Choueiri, M. Atkins, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444.

M. Sznol, A. Hotson, L. Fong, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies.

C. Drake, I. Lowy, A. Korman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.

S. Penugonda, A. Tolcher, P. LoRusso, 2021 .

A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma.

A. Pavlick, S. O’Day, E. Hersh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).

G. Giaccone, F. Hodi, S. Gettinger, 2015 .

620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion

R. Ramlau, E. Antonarakis, N. Vogelzang, 2021, Annals of Oncology.

Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.

J. Powderly, A. Spira, D. Loo, 2021, Journal of Clinical Oncology.

AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

L. Horvath, J. Powderly, L. Seitz, 2019, Journal of Clinical Oncology.

Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Previously Treated, Metastatic Renal Cell Carcinoma (MRCC)

David C. Smith, T. Choueiri, M. Atkins, 2012 .

Abstract P2-11-06: Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer

S. Adams, L. Molinero, J. Diamond, 2016 .

Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

F. Hodi, G. Fine, O. Hamid, 2013 .

Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors

J. Hamm, Gongfu Zhou, A. Naing, 2022, Cancer.

Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study

J. Bendell, A. Naing, D. Catenacci, 2022, The oncologist.

204 Combining FT536, a pan-tumor targeting CAR NK cell therapy, with CD16 engagers provides a coordinated targeting strategy to overcome tumor heterogeneity

Shohreh H Sikaroodi, Bryan M. Hancock, J. Powderly, 2022, Regular and Young Investigator Award Abstracts.

Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature.

A. Tolcher, P. Moore, J. Wigginton, 2016 .

1049OSAFETY AND EFFICACY OF MPDL3280A (ANTI-PDL1) IN COMBINATION WITH BEVACIZUMAB (BEV) AND/OR CHEMOTHERAPY (CHEMO) IN PATIENTS (PTS) WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS.

H. Hurwitz, J. Bendell, M. Pishvaian, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

730MO First-in-human phase I study of INCAGN02390, a TIM-3 monoclonal antibody antagonist in patients with advanced malignancies

J. Janik, A. Balmanoukian, O. Hamid, 2022, Annals of Oncology.

Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies

J. Powderly, A. Spira, A. Udyavar, 2019, Annals of Oncology.

Abstract CT209: A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors (NCT05054348)

M. Costa, P. Woodard, J. Powderly, 2022, Cancer Research.

3110 Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma: A phase IB trial

J. Nemunaitis, A. Heydebreck, J. Gulley, 2015 .

1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours

A. Italiano, J. Bendell, B. Carneiro, 2020 .

Safety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors.

A. Tolcher, M. Blaney, A. Patnaik, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors

R. Ferris, N. Rizvi, J. Norton, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

J. Taube, C. Drake, Lieping Chen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

T. Choueiri, R. Heist, B. Rini, 2020 .

513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study

G. Giaccone, F. Hodi, S. Gettinger, 2015 .

Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients

K. Blackwell, H. Lyerly, M. Morse, 2011, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.

S. Piha-Paul, R. Carvajal, J. Goldman, 2020 .

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)

U. Banerji, J. Powderly, N. Lakhani, 2024, ESMO open.